Please select the option that best describes you:
How does avidity on DOTATATE PET impact your choice of whether to start somatostatin analogues in metastatic neuroendocrine tumors?
Would a negative dotatate PET change management for a patient for whom you were planning to start SSAs?
Answer from: Medical Oncologist at Academic Institution
A negative DOTATATE scan is predictive for a lack of response to SSA therapy including Lutathera so I would not use octreotide or lanreotide for this patient and I would choose something else for treatment. (See for example Lee et al., PMID 32886441)
Sign in or Register to read more